



SPTO Form 1449 U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No. 351044-0014		Serial No. 10/616,321				
INFORMATION DISCLOSURE STATEMENT		Applicant(s):.. Clouatre						
		Filing Date: July 7, 2003			Group: 1614			
U.S. PATENT DOCUMENTS								
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)	
LS	A1	5,086,057	04 February 1992	Sasagawa	A01N	43/54	25 April 1991	
FOREIGN PATENT DOCUMENTS								
Examiner Initial		Document No.	Publication Date	Country	Class	Subclass	Translation	
							YES	NO
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)								
	C1	International Search Report for PCT/US04/21542						
EXAMINER /Layla Soroush/						DATE CONSIDERED		
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. **Copies of references not provided at the time of this submission.</small>								

FORM PTO-1449 (Substitute)			ATTY. DOCKET NO.	SERIAL NO.			
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)			APPLICANT CLOUATRE				
			FILING DATE July 7, 2003	GROUP			
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
LS	AA	20030119913	06/2003	Ohia, et al.	514	574	
	AB	20020187943	12/2002	Majeed, et al.	514	27	
	AC	6,476,071	11/2002	Clouatre, et al.	514	557	
	AD	6,221,901	04/2001	Shrivastava, et al.	514	458	
	AE	5,914,326	06/1999	McCarty, et al.	514	188	
	AF	5,783,603	07/1998	Majeed, et al.	514	574	
	AG	5,656,314	08/1997	Moffett, et al.	426	271	
	AH	3,993,668	11/1976	Guthrie, et al.	260	343.6	
	AI	3,919,254	11/1975	Guthrie, et al.	260	343.6	
↓	AJ	3,767,678	10/1973	Guthrie, et al.	260	343.6	
↓	AK	3,764,692	10/1973	Lowenstein	424	279	
FOREIGN PATENT DOCUMENTS							
LS	AL	WO-02/078616	10/2002	Ohia, et al.			
LS	AM	WO 02/14477	02/2002	Majeed, et al.			
	AN						
	AO						
	AP						
OTHER PRIOR ART (Including Author, Title, Date, Page(s) Etc.)							
AR	SEE ATTACHED SHEETS						
AS							
AT							
EXAMINER /Layla Soroush/			DATE CONSIDERED				
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

LIST OF PRIOR ART CITED BY APPLICANT**Sheet 2 of 3****Dallas L. Clouatre****TREATING CACHEXIA AND EXCESSIVE CATABOLISM WITH (-)-HYDROXYCITRIC ACID****July 7, 2003****OTHER U.S. PATENT DOCUMENTS**

LS		5,626,849	06/1997	Hastings, et al.	424	195.1	

OTHER PRIOR ART

Anonymous. Dronabinol (Marinol/Roxane). WholeHealthMD.

<http://www.wholehealthmd.com/refshelf/drugs>.Barber MD, et al. Effect of a fish oil-enriched nutritional supplement on metabolic mediators in patients with pancreatic cancer cachexia. *Nutr Cancer*. 2001;40(2):118-24.Hackenschmidt J, et al. Stimulation of acetyl-CoA carboxylase by (-)-Hydroxycitrate. *FEBS Lett.* 1972 Oct 15;27(1):131-133.Heymsfield SB, et al. Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent: a randomized controlled trial. *JAMA*. 1998;280:1596-1600; also Mattes RD, Bormann L. Effects of (-)-hydroxycitric acid on appetitive variables. *Physiol Behav*. 2000 Oct 1;71(1-2):87-94.Inui A. Cancer anorexia-cachexia syndrome: current issues in research and management. *CA Cancer J Clin*. 2002 Mar-Apr;52(2):72-91.Laviano A, et al. Neurochemical mechanisms for cancer anorexia. *Nutrition*. 2002 Jan;18(1):100-5.McCarty MF. Promotion of hepatic lipid oxidation and gluconeogenesis as a strategy for appetite control. *Medical Hypotheses* 1994;42:215-225.Nandi J, et al. Central mechanisms involved with catabolism. *Curr Opin Clin Nutr Metab Care*. 2002 Jul;5(4):407-18.Ohia SE, et al. Safety and mechanism of appetite suppression by a novel hydroxycitric acid extract (HCA-SX). *Mol Cell Biochem*. 2002 Sep;238(1-2):89-103.

Roubenoff R. Catabolism of aging: is it an inflammatory process? *Curr Opin Clin Nutr Metab Care.* 2003 May;6(3):295-9.

Roubenoff R, et al. Role of cytokines and testosterone in regulating lean body mass and resting energy expenditure in HIV-infected men. *Am J Physiol Endocrinol Metab.* 2002 Jul;283(1):E138-45.

Sato T, et al. Involvement of plasma leptin, insulin and free tryptophan in cytokine-induced anorexia. *Clin Nutr.* 2003 Apr;22(2):139-46.

Sullivan AC, Triscari J. Metabolic regulation as a control for lipid disorders. I. Influence of (-)-hydroxycitrate on experimentally induced obesity in the rodent. *American Journal of Clinical Nutrition* 1977;30:767-776.

Sullivan, Ann C. and Joseph Triscari. Possible interrelationship between metabolite flux and appetite. In D. Novin, W. Wyriwicka and G. Bray, eds., *Hunger: Basic Mechanisms and Clinical Implications* (New York: Raven Press, 1976) 115-125.

Sullivan AC, Gruen RK. Mechanisms of appetite modulation by drugs. *Federation Proceedings* 1985;44,1:139-144.

Triscari J, Sullivan AC. Comparative effects of (-)-hydroxycitrate and (+)-*allo*-hydroxycitrate on acetyl CoA carboxylase and fatty acid and cholesterol synthesis *in vivo*. *Lipids* April 1977;12(4): 357-363.